ArticleNature communications2019
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 4 pooled it
22.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 4 syntheses or guidelines pooled it, 361 citations in OpenAlex.
- Spontaneous complete regression of congenital brain tumors - a systematic literature review and case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- A systematic study of molecular diagnosis, treatment, and prognosis in infant-type hemispheric glioma: An individual patient data meta-analysis of 164 patients.Neuro-oncology · 2026Pooled it
- Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.International journal of clinical oncology · 2023Guideline
- Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.Archives of pathology & laboratory medicine · 2022Guideline
- NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Cancer discovery · 2024Trial
- Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).Neuro-oncology · 2022Trial
- Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.Neuro-oncology · 2022Trial
- Suprasellar Desmoplastic Infantile Ganglioglioma in a 7-Month-Old Infant: A Rare Diagnostic Consideration in Infant Suprasellar Masses.Clinical case reports · 2026Article
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Article
- Single-cell multi-omic analyses resolve the cellular diversity of ALK/ROS1/MET/NTRK-fused gliomas in infants and older children.bioRxiv : the preprint server for biology · 2026Article
- A Nationwide Central Diagnosis for Pediatric CNS Tumors in Japan: The JCCG Brain Tumor and Pathology Committees.Cancer science · 2026Article
- CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor.Discover oncology · 2026Article
- A Patient With NovelJTO clinical and research reports · 2026Article
- From blunt tools to bullseyes: The impact of targeted therapy in pediatric neuro-oncology.Neuro-oncology advances · 2026Review
- TRK inhibitors in pediatric gliomas.Neuro-oncology advances · 2026Review
- The molecular profile of gliomas in adolescents and young adults.Neuro-oncology advances · 2026Review
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- Long-Read Transcriptome Sequencing and Functional Validation Reveals Novel and Oncogenic Gene Fusions in Fusion Panel-Negative Gliomas.bioRxiv : the preprint server for biology · 2026Article
- Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development.Cancer metastasis reviews · 2026Review
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors at 20 institutions in 10 countries.
Ana S Guerreiro StucklinDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-3136-9241
Scott RyallDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Kohei FukuokaThe Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Michal ZapotockyThe Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Alvaro LassalettaDepartment of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Christopher LiDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Taylor BridgeDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Byungjin KimDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Anthony ArnoldoDepartment of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Paul E KowalskiDepartment of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Yvonne ZhongDepartment of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Monique JohnsonDepartment of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Claire LiDepartment of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-9326-9583
Arun K RamaniCentre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Robert SiddawayDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Liana Figueiredo NobreThe Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Pasqualino de AntonellisDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Christopher DunhamDivision of Anatomic Pathology, British Columbia Children's Hospital, Vancouver, BC, Canada.
Sylvia ChengDepartment of Pediatrics, The University of British Columbia, Vancouver, BC, Canada.
Daniel R BouéDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Jonathan L FinlayDivision of Hematology/Oncology/Bone Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH, USA.
Scott L CovenDivision of Hematology/Oncology/Bone Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH, USA.
Inmaculada de PradaDepartment of Pathology, Hospital Universitario Niño Jesús, Madrid, Spain.
Marta Perez-SomarribaDepartment of Pediatric Hematology and Oncology, Hospital Universitario Niño Jesús, Madrid, Spain.
Claudia C FariaDivision of Neurosurgery, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal.
Michael A GrotzerDepartment of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Elisabeth RushingInstitute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
David SumerauerSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Josef ZamecnikSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Lenka KrskovaSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Miguel Garcia ArizaDepartment of Pediatric Oncology, Hospital Cruces, Bilbao, Spain.
Ofelia CruzDepartment of Pediatric Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.
Andres Morales La MadridDepartment of Pediatric Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.
Palma SolanoDepartment of Pediatric Oncology, Hospital Infantil Virgen del Rocio, Sevilla, Spain.
Keita TerashimaChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Yoshiko NakanoDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5394-8194
Koichi IchimuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3851-2349
Motoo NaganeDepartment of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0018-1652
Hiroaki SakamotoDepartment of Pediatric Neurosurgery, Osaka City General Hospital, Osaka, Japan.
Maria Joao Gil-da-CostaDivision of Pediatric Hematoncology, University Hospital de São João, Porto, Portugal.
Roberto SilvaDepartment of Pathology, University Hospital de São João, Porto, Portugal.
Donna L JohnstonDivision of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
Jean MichaudDepartment of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada.
Bev WilsonDepartment of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Frank K H van LandeghemDepartment of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada.
Angelica OviedoDepartment of Anatomic Pathology, Dalhousie University, Halifax, NS, Canada.
P Daniel McNeelyDivision of Neurosurgery, IWK Health Centre, Halifax, NS, Canada.
Bruce CrooksDivision of Hematology-Oncology, IWK Health Centre, Halifax, NS, Canada.
Iris FriedThe Department of Pediatric Hematology Oncology, Hadassah Medical Center, Jerusalem, Israel.
Nataliya ZhukovaChildren's Cancer Centre, Royal Children's Hospital, Melbourne, Australia.
Jordan R HansfordChildren's Cancer Centre, Royal Children's Hospital, Melbourne, Australia.ORCID http://orcid.org/0000-0001-7733-383X
Amulya NageswararaoDivision of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN, USA.
Livia GarziaDepartment of Medicine, McGill University, Montreal, QC, Canada.
Mary ShagoDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Michael BrudnoCentre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Meredith S IrwinDepartment of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Ute BartelsDepartment of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Vijay RamaswamyThe Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-6557-895X
Eric BouffetDepartment of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Michael D TaylorDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Uri TaboriDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Cynthia HawkinsDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada. cynthia.hawkins@sickkids.ca.
Hospital for Sick Children · CAUniversity of Toronto · CACharles University · CZNationwide Children's Hospital · USHospital de São João · PTHospital Infantil Universitario Niño Jesús · ESHospital Sant Joan de Déu Barcelona · ESIzaak Walton Killam Health Centre · CARoyal Children's Hospital · AUUniversity of Alberta · CAUniversity of British Columbia · CAChildren's Hospital of Eastern Ontario · CADalhousie University · CAHadassah Medical Center · ILHospital de Cruces · ESHospital Universitario Virgen del Rocío · ESKyorin University · JPMayo Clinic in Arizona · USMcGill University · CANational Center For Child Health and Development · JP
Funding
Canadian Cancer Society Research Institute (Société Canadienne du Cancer) 702296Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 159805
Abstract
Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harbor RAS/MAPK pathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.
Indexed as
DNA MethylationGene Expression Regulation, NeoplasticAnaplastic Lymphoma KinaseBrain NeoplasmsEpigenomicsExome SequencingFemaleGliomaHumansInfantInfant, NewbornMaleProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-metReceptor Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseMET protein, humanProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-metReceptor Protein-Tyrosine KinasesReceptor, trkAROS1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.